These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32044322)

  • 1. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
    Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
    Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells.
    Hu H; Zhang XW; Li L; Hu MN; Hu WQ; Zhang JY; Miao XK; Yang WL; Mou LY
    Eur J Pharmacol; 2021 Oct; 908():174346. PubMed ID: 34270985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
    Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
    Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib.
    Jin Q; Zheng J; Chen M; Jiang N; Xu X; Huang F
    Oxid Med Cell Longev; 2021; 2021():6633867. PubMed ID: 33763171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K; Wang L; Wei A; Jia X; Liu X
    Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
    Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
    Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.